Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,873 shares of the biopharmaceutical company’s stock after purchasing an additional 2,612 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 0.9% of Greenwood Capital Associates LLC’s portfolio, making the stock its 27th largest holding. Greenwood Capital Associates LLC’s holdings in Regeneron Pharmaceuticals were worth $8,650,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. New Mexico Educational Retirement Board lifted its position in Regeneron Pharmaceuticals by 4.2% during the 2nd quarter. New Mexico Educational Retirement Board now owns 5,000 shares of the biopharmaceutical company’s stock worth $3,118,000 after acquiring an additional 200 shares during the period. Mufg Securities Americas Inc. grew its holdings in Regeneron Pharmaceuticals by 7.9% during the second quarter. Mufg Securities Americas Inc. now owns 3,010 shares of the biopharmaceutical company’s stock worth $1,877,000 after acquiring an additional 221 shares during the period. Van ECK Associates Corp lifted its holdings in Regeneron Pharmaceuticals by 4.4% in the second quarter. Van ECK Associates Corp now owns 65,332 shares of the biopharmaceutical company’s stock valued at $40,737,000 after acquiring an additional 2,748 shares during the period. Nissay Asset Management Corp Japan boosted its position in shares of Regeneron Pharmaceuticals by 6.1% during the 2nd quarter. Nissay Asset Management Corp Japan now owns 30,636 shares of the biopharmaceutical company’s stock worth $19,103,000 after purchasing an additional 1,767 shares in the last quarter. Finally, Kimelman & Baird LLC increased its holdings in shares of Regeneron Pharmaceuticals by 154.9% in the 2nd quarter. Kimelman & Baird LLC now owns 27,671 shares of the biopharmaceutical company’s stock valued at $17,254,000 after purchasing an additional 16,815 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock valued at $1,090,030 over the last three months. 6.97% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on REGN shares. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, HSBC cut their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Fifteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $800.36.

Regeneron Pharmaceuticals Stock Down 1.7%

Shares of REGN stock opened at $794.19 on Friday. The stock’s 50 day simple moving average is $717.52 and its 200 day simple moving average is $718.38. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $847.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market capitalization of $81.77 billion, a price-to-earnings ratio of 19.63, a PEG ratio of 1.35 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the company posted $12.81 earnings per share. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.